Your browser doesn't support javascript.
CEC01-02 Development of mRNA-based vaccines
Toxicology Letters ; 368(Supplement):S2, 2022.
Article in English | EMBASE | ID: covidwho-2211540
ABSTRACT
Although mRNA vaccines have been published in 1993 by a French team (Prof. Meulien, Paris), their development has been hindered by the prejudice associated to the supposed fragility of mRNA. Actually, mRNA is a very robust biomolecule (it can be heated up to 90 degrees, frozen, lyophilized), easy to manufacture even at high scale and capable to lead to potent protein expression once administered naked or in nanoparticle formulations. Private investments in companies (for example CureVac created in 2000, BioNTech created in 2008 and Moderna created in 2011) have allowed to develop the potential of mRNA based therapies. The safety, versatility and efficacy of mRNA-based vaccines was evidenced during the COVID-19 pandemic less than one year after the publication of the sequence of SARS-CoV-2, an mRNA vaccine against COVID-19 was approved and marketed. More mRNA vaccines (against infectious diseases and cancer) are in clinical developments and are expected to be approved in the coming years. In addition, mRNA-based therapies using non-immunogenic formulations of mRNA are being developed. Thus, the potential of synthetic mRNA in medicine is just starting to be unraveled and this versatile biomolecule is expected to be the active pharmaceutical ingredient in many future prophylactic and therapeutic drugs. Copyright © 2022 Elsevier B.V.
Keywords

Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Vaccines Language: English Journal: Toxicology Letters Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Vaccines Language: English Journal: Toxicology Letters Year: 2022 Document Type: Article